Meta-analysis of the occurrence of hepatocellular carcinoma after the treatment of entecavir and tenofovir for chronic hepatitis B

Tang, Kaiyue; Cheng, Hong; Wang, Haiyan; Guo, Yueping

doi:10.1097/md.0000000000032894

Cited by 3 publications

(2 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The antiviral efficacy of entecavir is related to the patient's immune function, hepatitis activity, cytotoxicity, and antigen-related cell function. Entecavir alone is not effective for some patients [11] . Peginterferon α-2b injection can induce cells to secrete proteins with antiviral functions, thereby inhibiting HBV-DNA.…”

Section: Discussionmentioning

confidence: 98%

Clinical Efficacy and Incidence of Adverse Reactions of Entecavir Combined with Long-Acting Interferon in Treating Hepatitis B

Yang

2023

JCNR

View full text Add to dashboard Cite

Objective: To explore and analyze the clinical efficacy and incidence of adverse reactions of entecavir combined with long-acting interferon in treating hepatitis B. Methods: The study was conducted from January 2020 to December 2022, and the research subjects were 69 hepatitis B patients admitted to our hospital. The patients were divided into a research group (n = 35) and a control group (n = 34). Patients in the control group were treated with entecavir, while patients in the study group were treated with entecavir combined with long-acting interferon. The antiviral efficacy, liver function indicators, clinical effectiveness, and incidence of adverse reactions were compared between the two groups. Results: The HBV-DNA negative conversion rate and HBeAg seroconversion rate of the patients in the study group were higher than those of the control group, and the virological breakthrough rate was lower than that of the control group (P < 0.05); the alanine transaminase (ALT), aspartate aminotransferase (AST), and total bilirubin (TBIL) levels of the patients in the study group were all lower after treatment. In the control group, the albumin (ALB) level was higher than that in the control group (P < 0.05). The clinical effective rate of patients in the study group was higher than that in the control group (P < 0.05); there was no significant difference in the incidence of adverse reactions between the two groups (P > 0.05). Conclusion: The treatment effect of entecavir combined with long-acting interferon in patients with hepatitis B is significant. It can effectively antiviral and improve the liver function of patients. The incidence of adverse reactions is low and can be promoted and applied.

show abstract

Section: Discussionmentioning

confidence: 98%

Clinical Efficacy and Incidence of Adverse Reactions of Entecavir Combined with Long-Acting Interferon in Treating Hepatitis B

Yang

2023

JCNR

View full text Add to dashboard Cite

show abstract

“…However, very few patients achieve sustained viral and clinical remission from the therapy. In this regard, antiviral therapy with nucleoside/nucleotide analogs (NAs), such as entecavir and tenofovir prodrugs, significantly reduces the incidence of cirrhosis and HCC [ 13 , 14 , 15 ]. This review summarizes the current and emerging promising therapeutic strategies for chronic HBV treatment and prevention ( Figure 1 ).…”

Section: Introductionmentioning

confidence: 99%

Chronic Hepatitis B Infection: New Approaches towards Cure

Ogunnaike,

Das,

Raut

et al. 2023

Biomolecules

View full text Add to dashboard Cite

Chronic hepatitis B virus (HBV) infection leads to the development of cirrhosis and hepatocellular carcinoma. Lifelong treatment with nucleotides/nucleoside antiviral agents is effective at suppressing HBV replication, however, adherence to daily therapy can be challenging. This review discusses recent advances in the development of long-acting formulations for HBV treatment and prevention, which could potentially improve adherence. Promising new compounds that target distinct steps of the virus life cycle are summarized. In addition to treatments that suppress viral replication, curative strategies are focused on the elimination of covalently closed circular DNA and the inactivation of the integrated viral DNA from infected hepatocytes. We highlight promising long-acting antivirals and genome editing strategies for the elimination or deactivation of persistent viral DNA products in development.

show abstract

Efficacy and safety of therapeutic vaccines for the treatment of chronic hepatitis B: A systematic review and meta-analysis of randomized controlled trials update

Geta,

Mengistu,

Yizengaw

et al. 2024

Medicine

View full text Add to dashboard Cite

Background: Most people diagnosed with chronic hepatitis B (CHB) need treatment to help reduce the risk of liver disease and limit disease transmission. Therapeutic vaccine (TV) candidates have been under study for their clinical effects on inducing HBV-specific host immune responses. This review aimed to systematically synthesize updated evidence on the efficacy and safety of TVs in patients with CHB. Methods: This systematic review was performed by searching different databases from January to February 2021. Completed randomized controlled trials that reported TVs' efficacy and/or safety for treating CHB compared with the standard of care (SOC) or placebo were included. Efficacy and safety estimates were reported as the logarithm of the odds ratio and risk differences, respectively. I 2 > 50% was considered significant heterogeneity. Significant publication bias was considered when Egger’s test P value < .10. The risk of bias was assessed using the Cochrane Risk of Bias tool. The GRADE methodology was used to assess the certainty of the evidence for each outcome. Results: Twenty-four articles with 2889 pooled samples were included. TVs made a significant difference in hepatitis B envelope antigen (HBeAg) SC (log OR = 0.76, P = .01) and (log OR = 0.40, P = .03) compared to placebo and combination therapy, respectively. HBeAg SC was significantly affected by TVs at the end of follow up (log OR = 0.49, P = .01), with significant HBsAg mean difference (MD = −0.62, P = .00). At the end of treatment, the TVs had no significant effect on HBV DNA negativity over the SOC (log OR = 0.62, P = .09) or placebo (log OR = −0.07, P = .91). TVs do not significantly affect the risk of serious adverse events (RD 0.02, 95% CI 0.00–0.04). Conclusion: In patients with CHB, TVs had significant effects on HBeAg SC compared to the SOC or placebo. There was no significant difference between serious adverse events. TVs are promising treatment strategy to overcome CHB.

show abstract

Meta-analysis of the occurrence of hepatocellular carcinoma after the treatment of entecavir and tenofovir for chronic hepatitis B

Cited by 3 publications

References 33 publications

Clinical Efficacy and Incidence of Adverse Reactions of Entecavir Combined with Long-Acting Interferon in Treating Hepatitis B

Clinical Efficacy and Incidence of Adverse Reactions of Entecavir Combined with Long-Acting Interferon in Treating Hepatitis B

Chronic Hepatitis B Infection: New Approaches towards Cure

Efficacy and safety of therapeutic vaccines for the treatment of chronic hepatitis B: A systematic review and meta-analysis of randomized controlled trials update

Contact Info

Product

Resources

About